{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:41:25Z","timestamp":1783395685954,"version":"3.54.6"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"DOI":"10.1086\/491714","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T15:26:15Z","timestamp":1133796375000},"page":"S51-S57","source":"Crossref","is-referenced-by-count":135,"title":["The Role of Vancomycin in the Treatment Paradigm"],"prefix":"10.1093","volume":"42","author":[{"given":"Dennis L.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"key\n\t\t\t\t20171014043223_ref1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/131.4.367","article-title":"Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus","volume":"131","author":"Sande","year":"1975","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7326\/0003-4819-97-4-496","article-title":"Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study","volume":"97","author":"Korzeniowski","year":"1982","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014043223_ref3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/jama.1977.03280170050028","article-title":"Vancomycin: a second look","volume":"238","author":"Esposito","year":"1977","journal-title":"JAMA"},{"issue":"Suppl","key":"key\n\t\t\t\t20171014043223_ref4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinids\/3.Supplement_2.S250","article-title":"Vancomycin therapy for infective endocarditis","volume":"3","author":"Geraci","year":"1981","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","article-title":"Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users","volume":"34","author":"Small","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/j.1875-9114.1997.tb03788.x","article-title":"Retrospective evaluation of therapies for Staphylococcus aureus endocarditis","volume":"17","author":"Gentry","year":"1997","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014043223_ref7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171014043223_ref8","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171014043223_ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/00365540410015907","article-title":"Treatment of vancomycin-intermediate Staphylococcus aureus endocarditis with linezolid","volume":"36","author":"Leung","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1086\/383027","article-title":"Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"38","author":"Woods","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref14","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2014United States, 2002","volume":"51","author":"Sievert","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014043223_ref15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","article-title":"Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance","volume":"1","author":"Hiramatsu","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref16","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1128\/AAC.46.8.2595-2601.2002","article-title":"In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens","volume":"46","author":"Petersen","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref18","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1128\/AAC.47.12.3764-3767.2003","article-title":"Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model","volume":"47","author":"Hermsen","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref20","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structured infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref21","first-page":"118","article-title":"Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis","volume":"88","author":"Sande","year":"1976","journal-title":"J Lab Clin Med"},{"key":"key\n\t\t\t\t20171014043223_ref22","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1128\/AAC.48.10.4016-4019.2004","article-title":"In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations","volume":"48","author":"Shelburne","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref23","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/AAC.47.12.3960-3963.2003","article-title":"Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref24","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1128\/AAC.47.12.3768-3773.2003","article-title":"Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model","volume":"47","author":"Lee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014043223_ref26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014043223_ref27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20171014043223_ref28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","article-title":"Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients","volume":"359","author":"Gillet","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014043223_ref29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/38.5.865","article-title":"Penetration of vancomycin into human lung tissue","volume":"38","author":"Cruciani","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014043223_ref32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t20171014043223_ref33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/jac\/35.2.352","article-title":"Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections","volume":"35","author":"Wysocki","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.40.3.696","article-title":"Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections","volume":"40","author":"James","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref35","first-page":"876","article-title":"Therapy of ventilator-associated pneumonia: a patient-based approach based on the ten rules of \u201cThe Tarragona Strategy.\u201d Intensive Care Med","volume":"29","author":"Sandiumenge","year":"2003","journal-title":""},{"key":"key\n\t\t\t\t20171014043223_ref36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20171014043223_ref37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014043223_ref38","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref39","article-title":"Pulmonary epithelial lining fluid (ELF) as a privileged site: daptomycin in pulmonary infections [abstract 60.005]","volume-title":"Program and abstracts of the 11th International Congress on Infectious Diseases (Cancun, Mexico)","author":"Alder","year":"2004"},{"key":"key\n\t\t\t\t20171014043223_ref40","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.44.12.3408-3413.2000","article-title":"Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","article-title":"Linezolid eradicates MRSA better than vancomycin from surgical-site infections","volume":"188","author":"Weigelt","year":"2004","journal-title":"Am J Surg"},{"key":"key\n\t\t\t\t20171014043223_ref42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014043223_ref44","article-title":"Protein binding of dalbavancin using isothermal titration microcalorimetry [abstract A1385]","volume-title":"Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego)","author":"Cavaleri","year":"2002"},{"key":"key\n\t\t\t\t20171014043223_ref45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/42\/Supplement_1\/S51\/20907292\/42-Supplement_1-S51.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:43:16Z","timestamp":1706784196000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/42\/Supplement_1\/S51\/276380\/The-Role-of-Vancomycin-in-the-Treatment-Paradigm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":45,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1086\/491714","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,1,1]]},"published":{"date-parts":[[2006,1,1]]}}}